Patient/Sex/Age (y) | Clinical Presentation | Stent (mm)* | Complication | Complication Management | Stenosis Degree (%) | Neurologic Outcome | Follow-Up | ||
---|---|---|---|---|---|---|---|---|---|
Initial | Poststenting | DSA | Ischemic | ||||||
1/M/48 | TIA | G 2.5 × 9 | None | NA | 65 | NA | Fail | NA | NA |
2/M/51 | TIA | G 3.0 × 9 | Rupture | NA | 75 | NA | Death | NA | NA |
3/M/71 | TIA | S 2.5 × 9 | None | NA | 70 | 0 | Excellent | NA | None, 25 mo |
4/M/67 | TIA | S 2.5 × 15 | AT | Abciximab 8 mg IA | 80 | 5 | Excellent | 6 mo, no RS | None, 17 mo |
5/F/74 | TIA | S 2.5 × 15 | None | NA | 70 | 0 | Excellent | NA | None, 17 mo |
6/F/58 | TIA, infarct | S 2.5 × 18, S 2.5 × 12 | Rupture, AT | Second stent overlap, abciximab 10 mg IA | 90 | 0 | Good | 10 mo RS | None, 15 mo |
7/M/66 | TIA, infarct | F 2.5 × 9 | None | NA | 60 | 0 | Excellent | NA | None, 11 mo |
8/M/60 | Infarct | F 2.5 × 9 | None | NA | 65 | 0 | Excellent | NA | None, 11 mo |
9/F/52 | Infarct | F 2.5 × 9 | None | NA | 70 | 0 | Good | 6 mo, no RS | None, 9 mo |
10/F/49 | TIA, infarct | F 2.5 × 9, F 2.5 × 12 | Stent jumping, AT, minor stroke | Second stent overlap, abciximab 10 mg IA, IV heparin | 50 | 0 | Fair | 3 mo, no RS | None, 9 mo |
11/M/60 | TIA | F 2.75 × 12 | AT, SAT | Abciximab 10 mg IA, IA thrombolysis | 70 | 0 | Fair | 3 mo, no RS | None, 9 mo |
12/M/67 | TIA | F 2.5 × 9 | AT | Abciximab 10 mg IA | 60 | 0 | Good | 6 mo, no RS | None, 8 mo |
13/M/60 | TIA | S 2.5 × 9 | AT | Abciximab 16 mg 1A | 70 | 0 | Excellent | NA | None, 7 mo |
14/M/63 | Infarct | S 2.5 × 9 | AT | Abciximab 16 mg IA | 65 | 0 | Excellent | NA | None, 4 mo |
15/M/41 | Infarct | S 2.5 × 12 | None | NA | 60 | 0 | Excellent | NA | None, 3 mo |
16/F/71 | TIA | S 2.5 × 15 | AT | Abciximab 10 mg IA | 60 | 0 | Excellent | NA | None, 2 mo |
17/M/53 | Infarct | S 2.5 × 12 | AT | Abciximab 10 mg IA | 70 | 0 | Excellent | NA | None, 1 mo |
Note.—Abbreviations: AT, acute in-stent thrombosis; F, Flexmaster (JoMed); G, Gfx (AVE; Medtronic); IA, intra-arterial; IV, intravenous; NA, not applicable; RS, in-stent restenosis; S, S660 (AVE; Medtronic); and SAT, subacute in-stent thrombosis.
* Stent implantation was successful in all patients except patient 1.